
|Videos|September 21, 2016
Were PCSK9 Inhibitors Overhyped?
Author(s)Lauren Santye, Assistant Editor
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.
Advertisement
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
'Beyond Weight Loss': Emerging Studies Show How GLP-1 Receptor Agonists May Impact Addiction Behaviors
2
New Drug Approach Targets KRAS-Mutant Lung Cancer to Overcome Therapy Resistance
3
FDA Approves Denosumab Biosimilars Boncresa and Oziltus for Osteoporosis-, Cancer-Related Bone Loss
4
The Role of the Pharmacist in the Management of Psychosis in Parkinson’s Disease
5










































































































































































































